Extended Data Fig. 4: Additional information on Innate immune cell alterations in patients with MIS-C at T1, T2 and T3 phases compared to age-matched healthy controls.

Innate immune alterations persist in MIS-C. a, Monocyte CD14 (toll-like receptor 4 co-receptor) expression (MFI) was significantly reduced in patients compared with healthy controls. b, Monocyte CD64 (Fc gamma receptor 1) expression (MFI) was increased in acute illness phase (T1) compared with healthy controls and later illness phases (T2 and T3). c, Classical monocyte proportions remained unchanged relative to healthy controls and illness phases. d, Classical monocytes had significantly reduced CD86 (T cell co-stimulant) expression (MFI) in acute and resolution illness phases (T1 and T2) in comparison with healthy controls and convalescence (T3). Abbreviations: MFI, median fluorescence intensity. In figures, box and whisker plots, bottom border represents 25th percentile; line bisecting the shaded region of each box represents median; upper border of the box, 75th percentile. The whiskers represent extreme 1.5 times the 75th (highest) and 25th (lowest) values and markers beyond the extreme line are outliers. Dots are colored by serology result; positive (red) and negative (blue), with the red asterisk indicating the patient positive by RT-PCR for SARS-CoV-2. Healthy Controls are shaded as grey and patients with MIS-C as yellow. Significance testing between patients by phase of illness (T1 (n = 23 samples), T2 (n = 14 samples), T3 (n = 10 samples) was using two-sided Wilcoxon rank sum tests, with correction for multiple comparisons.